AC
CTOR

Armistice Capital’s Citius Oncology CTOR Stock Holding History

Armistice Capital’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.7M Buy
9,188,855
+3,604,775
+65% +$3.62M 0.1% 119
2025
Q4 		$5.58M Sell
5,584,080
-2,091,831
-27% -$3M 0.07% 124
2025
Q3 		$15.6M Buy
+7,675,911
New +$16.6M 0.23% 69

Other funds holding CTOR

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Armistice Capital's CTOR Position: Q1 2026 in Review

Armistice Capital increased its Citius Oncology (CTOR) stake by 65% in Q1 2026, buying an estimated $3.62M and bringing the position to 9,188,855 shares worth $5.7M. The position accounts for 0.1% of the portfolio, ranked #119.

Armistice Capital first reported a position in CTOR in Q3 2025 and has held it in 3 quarters since. The position peaked at $15.6M in Q3 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • Armistice Capital held 9,188,855 shares of Citius Oncology worth $5.7M as of Q1 2026.
  • Armistice Capital bought 3,604,775 Citius Oncology shares in Q1 2026, an estimated $3.62M.
  • Citius Oncology made up 0.1% of Armistice Capital's portfolio in Q1 2026, its #119 holding.
  • Armistice Capital first reported a position in Citius Oncology in Q3 2025 and has held it in 3 quarters since.
  • Armistice Capital's Citius Oncology position peaked at $15.6M in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.